Merck COVID pill Molnupiravir likely to get WHO recommendation in February
New Delhi: The World Health Organization (WHO) is currently reviewing Merck's COVID-19 antiviral oral pill molnupiravir and a recommendation will likely be made by early February, an agency official said on Friday.
Janet Diaz, WHO lead on clinical management, said the WHO'S Guidelines Development Group is also getting ready to review Pfizer's oral pill. "We will be looking at that (Pfizer oral pill) data in early February for publication likely at the end of that month."
Late on Thursday, a WHO panel recommended use of two drugs by Eli Lilly, and GlaxoSmithKline and Vir Biotechnology for COVID-19 patients, adding treatment options as the fast-spreading Omicron variant renders many ineffective.
Read also: WHO panel recommends Eli Lilly Baricitinib, GSK-Vir Biotechnology drug for COVID treatment
Talking about monoclonal antibody treatments, Diaz told Reuters some monoclonals are showing impaired neutralization against the highly infectious Omicron and may be less effective against it.
However, she said it was not a 'game changer' as multiple therapeutic options are currently available for COVID-19.
"We are also monitoring antivirals for development of resistance."
Medical Dialogues had earlier reported that Lupin, Aurobindo Pharma had launched antiviral medication Molnupiravir in the country for the treatment of COVID-19.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.